Masaki Kanazu

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 10

Top Topics

Tyrosine Kinase

Small Cell Lung Cancer

Chemotherapy Induced

Top Venues

Thoracic cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Mototsugu Shimokawa, Masaki Kanazu, Ryusei Saito, Masahide Mori, Atsuhisa Tamura, Yoshio Okano, Yuka Fujita, Takeo Endo, Mitsuru Motegi, Shohei Takata, Toshiyuki Kita, Noriaki Sukoh, Fumitaka Mizuki, Mitsuhiro Takenoyama, Shinji Atagi
Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan. Thoracic cancer (2023)
Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima, Fumiyoshi Ohyanagi, Takehiro Tozuka, Tsugitomi Ryosuke, Toshio Sakatani, Atsushi Horiike, Takahiro Yoshizawa, Masafumi Saiki, Yuichi Tambo, Junji Koyama, Masaki Kanazu, Keita Kudo, Yuko Tsuchiya-Kawano, Noriko Yanagitani, Makoto Nishio
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01). Thoracic cancer (2022)
Yuki Akazawa, Aki Yoshikawa, Masaki Kanazu, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori
Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study. Thoracic cancer 13 (17) (2022)
Reina Hara, Masaki Kanazu, Ami Iwai, Tomoki Kuge, Mikako Ishijima, Takeshi Uenami, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori
EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib. Thoracic cancer 12 (9) (2021)
Tomoki Kuge, Fukuko Okabe, Yuji Yamamoto, Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori
Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report. Thoracic cancer 12 (12) (2021)
Yuji Yamamoto, Yukihiro Yano, Tomoki Kuge, Fukuko Okabe, Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Toshihiko Yamaguchi, Masahide Mori
Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study. Thoracic cancer 11 (11) (2020)
Masaki Kanazu, Masahide Mori, Madoka Kimura, Kazumi Nishino, Takayuki Shiroyama, Izumi Nagatomo, Shoichi Ihara, Kiyoshi Komuta, Hidekazu Suzuki, Tomonori Hirashima, Toru Kumagai, Fumio Imamura
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study. Thoracic cancer 12 (1) (2020)
Ryuya Edahiro, Masaki Kanazu, Hiroyuki Kurebe, Masahide Mori, Daichi Fujimoto, Yoshihiko Taniguchi, Hidekazu Suzuki, Katsuya Hirano, Toshihide Yokoyama, Mitsunori Morita, Yasushi Fukuda, Junji Uchida, Takeshi Makio, Motohiro Tamiya
Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. PloS one 14 (7) (2019)
Masaki Kanazu, Ryuya Edahiro, Hiroyuki Krebe, Kohei Nishida, Mikako Ishijima, Takeshi Uenami, Yuki Akazawa, Yukihiro Yano, Toshihiko Yamaguchi, Masahide Mori
Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series. Thoracic cancer 9 (12) (2018)
Masaki Kanazu, Takeshi Uenami, Yukihiro Yano, Saeko Nakatsubo, Yuki Hosono, Mikako Ishijima, Yuki Akazawa, Toshihiko Yamaguchi, Koji Urasaki, Masahide Mori, Soichiro Yokota
Case series of pleomorphic carcinomas of the lung treated with nivolumab. Thoracic cancer 8 (6) (2017)